Comprehensive analysis of competitive endogenous RNAs network: Identification and validation of prediction model composed of mRNA signature and miRNA signature in gastric cancer.
competing endogenous RNA
diagnosis
gastric cancer
least absolute shrinkage and selector operator
prognosis
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
12
2021
accepted:
22
02
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
ppublish
Résumé
Gastric cancer (GC), one of the most lethal malignant tumors, is highly aggressive with a poor prognosis, while the molecular mechanisms underlying it remain largely unknown. Although advanced imaging techniques and comprehensive treatment facilitate the diagnosis and survival of some GC patients, the precise diagnosis and prognosis are still a challenge. The present study used publicly available gene expression profiles from The Cancer Genome Atlas and Gene Expression Omnibus datasets including mRNA, micro (mi)RNA and circular (circ)RNA of GC to establish a competing endogenous RNA network (ceRNA). Further, the present study performed least absolute shrinkage and selector operator regression analysis on the hub RNAs to establish a prediction model with mRNA and miRNA. The ceRNA network contained 109 edges and 56 nodes and the visible network contains 13 miRNAs, 9 circRNAs and 34 mRNAs. The five mRNA-based signature were CTF1, FKBP5, RNF128, GSTM2 and ADAMTS1. The area under curve (AUC) value of the diagnosis training cohort was 0.9975. The prognosis of the high-risk group (RiskScore >4.664) was worse compared with that of the low-risk group (RiskScore ≤4.664; P<0.05) in the training cohort. The five miRNA-based signature were miR-145-5p, miR-615-3p, miR-6507-5p, miR-937-3p and miR-99a-3p. The AUC value of the diagnosis training cohort was 0.9975. The prognosis of the high-risk group (RiskScore >1.621) was worse compared with that of the low-risk group (RiskScore ≤1.621; P<0.05) in the training cohort. The validation cohorts indicated that both five mRNA and five miRNA-based signatures had strong predictive power in diagnosis and prognosis for GC. In conclusion, a ceRNA network was established for GC and a five mRNA-based signature and a five miRNA-based signature was identified that enabled diagnosis and prognosis of GC by assigning patient to a high-risk group or low-risk group.
Identifiants
pubmed: 35350591
doi: 10.3892/ol.2022.13270
pii: OL-23-05-13270
pmc: PMC8941526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
150Informations de copyright
Copyright: © Ding et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Entropy (Basel). 2021 Oct 19;23(10):
pubmed: 34682092
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cell. 2019 Nov 14;179(5):1033-1055
pubmed: 31730848
Hepatol Int. 2019 Sep;13(5):618-630
pubmed: 31321712
RNA. 2004 Oct;10(10):1507-17
pubmed: 15383676
Oncotarget. 2017 Aug 7;8(49):85463-85478
pubmed: 29156733
ESMO Open. 2021 Oct;6(5):100234
pubmed: 34461485
Front Oncol. 2018 May 28;8:179
pubmed: 29911069
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Front Cell Dev Biol. 2021 Nov 03;9:732036
pubmed: 34805143
Bratisl Lek Listy. 2017;118(2):71-76
pubmed: 28814085
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Br J Cancer. 2014 Apr 29;110(9):2291-9
pubmed: 24595006
J Cancer. 2019 Jun 2;10(13):2953-2960
pubmed: 31281472
Cancer. 2020 Jan 1;126(9):1929-1939
pubmed: 32031687
BMC Med. 2020 Sep 14;18(1):257
pubmed: 32921305
BMC Bioinformatics. 2019 Apr 2;20(1):167
pubmed: 30940067
Gut. 2021 May;70(5):829-837
pubmed: 33028667
World J Gastroenterol. 2021 Aug 21;27(31):5126-5151
pubmed: 34497440
Cancer Cell. 2018 Apr 9;33(4):721-735.e8
pubmed: 29622466
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Clin Cancer Res. 2019 May 15;25(10):3016-3025
pubmed: 30808771
Bioinformatics. 2019 Jun 1;35(11):1870-1876
pubmed: 30395191
Int Immunopharmacol. 2020 Nov;88:106868
pubmed: 32771948
PLoS One. 2018 Oct 18;13(10):e0206239
pubmed: 30335862
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Bioinformatics. 2016 Jun 1;32(11):1716-23
pubmed: 26826716
Biomed Pharmacother. 2018 May;101:406-413
pubmed: 29501762
Nat Commun. 2018 Oct 17;9(1):4319
pubmed: 30333487
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Oncol Rep. 2019 Feb;41(2):989-998
pubmed: 30431119
Psychoneuroendocrinology. 2012 Sep;37(9):1569-76
pubmed: 22459275
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Bioinformatics. 2000 May;16(5):412-24
pubmed: 10871264
Gastric Cancer. 2016 Jul;19(3):744-53
pubmed: 26233325
Cell Signal. 2019 Oct;62:109352
pubmed: 31260797
Gastric Cancer. 2021 Jul;24(4):835-843
pubmed: 33743111
IEEE Trans Pattern Anal Mach Intell. 2018 Dec;40(12):2992-3006
pubmed: 29990186
J Gene Med. 2021 May;23(5):e3330
pubmed: 33682985